Results

1–6 of 6 results for Michael A. Singer

BVA Analysis of Low- or High-Dose MCO-010 Optogenetics Therapy for Retinitis Pigmentosa: First Time 100-Week TOPLINE Results From a Phase 2b/3 Clinical trial (RESTORE)
Michael A. Singer, MD
Updates from the Field
2024
Phase 2 Study of Two Formulations of AR-1105 in Macular Edema (ME) Secondary to Retinal Vein Occlusion (RVO)
Michael A. Singer, MD
Annual Meeting Talks
2021
Two-Year Real-World Treat and Extend Patterns and Fluid Outcomes Among Neovascular Age-Related Macular Degeneration Patients Treated With Anti-VEGFs
Michael A. Singer, MD
Annual Meeting Talks
2020
Association Between Early Vision-Related Quality of Life (QoL) Outcomes and Anatomic Dryness in neovascular AMD and DME in the VIEW and FAME trials
Michael A. Singer, MD
On Demand Cases, Courses, and Papers
2019
The Translation of CST to Visual Function: Persistent DME and QOL Measures With FAc Implants in the FAME Study
Michael A. Singer, MD
Annual Meeting Talks
2018
An analysis of the phase 2 trial with intraviteal aflibercept and suprachoroidal
Michael A. Singer, MD
Updates from the Field
2017